Unprecedented pharmacological breakthroughs in oncology over the past decade
High costs of these novel anticancer drugs has placed considerable strain on the U.S. health care system.

Specialty tiers, coinsurance, and high deductible health plans mean patients are not immune to prices.

What did these frameworks set out to do?

- Help guide shared patient/physician decision making for cancer treatment choices
- Integrate cost and value into treatment planning

While these efforts are laudable, these frameworks have attracted a variety of criticisms.
Key questions to be addressed by the panel

• WHY do we need a more patient-centered framework?
• WHAT is important to patients, and how can we develop and implement a decision tool that truly meets the goals and priorities of individuals in daily clinical practice?
• HOW can we develop a scoring approach to help inform decision-making based on the various factors?

Today’s Panel

Henry Glick, PhD, Professor of Medicine, Perelman School of Medicine; Professor of Health Care Systems, Wharton School; University of Pennsylvania, Philadelphia, PA, USA

Ellen Miller Sonet, JD, MBA, Chief Strategy and Alliance Officer, CancerCare, New York, NY

Charles E. Phelps, PhD, MBA, University Professor & Provost Emeritus, Office of the Provost, University of Rochester, Gualala, CA, USA